Featuring an interview with Dr Adam Brufsky, including the following topics:
- Trastuzumab deruxtecan (T-DXd) for HER2-low breast cancer; recently presented findings from the DESTINY-BREAST04 trial (0:00)
- Impact of heterogeneous disease on the detection of HER2-low expression in patients with breast cancer (7:48)
- Case: A woman with low-volume, asymptomatic and nonvisceral ER-positive, HER2-low breast cancer (13:16)
- Case: A woman with high-volume, symptomatic and visceral HER2-low breast cancer; treating ER-negative, HER2-low disease (18:44)
- Toxicities associated with T-DXd (25:25)
- Ongoing trials evaluating T-DXd in earlier lines of therapy (31:28)
CME information and select publications
Research To Practice | Oncology Videos